Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » European Task Force on Atopic Dermatitis statement on sev...

Om AU

European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Letter › peer review

DOI

  • Andreas Wollenberg, Ludwig-Maximilians-Universität, Department of Dermatology I
    • ,
  • Carsten Flohr, Guy's and St Thomas' NHS Foundation Trust
    • ,
  • Dagmar Simon, University of Bern
    • ,
  • Michael J. Cork, Sheffield Hallam University
    • ,
  • Jacob P. Thyssen, Region Hovedstaden, Copenhagen Research Group for Inflammatory Skin (CORGIS)
    • ,
  • Thomas Bieber, University of Bonn
    • ,
  • Marjolein S. de Bruin-Weller, Utrecht University
    • ,
  • Stephan Weidinger, Kiel University
    • ,
  • Mette Deleuran
  • Alain Taieb, Université Bordeaux
    • ,
  • Carle Paul, Université de Toulouse
    • ,
  • Magdalena Trzeciak, Medical University of Gdansk
    • ,
  • Thomas Werfel, Hannover Medical School
    • ,
  • Julien Seneschal, Université Bordeaux
    • ,
  • Sebastien Barbarot, CHU Nantes
    • ,
  • Ulf Darsow, Technische Universität München
    • ,
  • Antonio Torrelo, Hospital Infantil Universitario Nino Jesus de Madrid
    • ,
  • Jean Francois Stalder, CHU Nantes
    • ,
  • Åke Svensson, Lund University
    • ,
  • Dirkjan Hijnen, Erasmus University Rotterdam
    • ,
  • Carlo Gelmetti, University of Milan
    • ,
  • Zsuzsanna Szalai, Pál National Children's Institute Budapest
    • ,
  • Uwe Gieler, Justus-Liebig University
    • ,
  • Linda De Raeve, Oncologisch Centrum
    • ,
  • Barbara Kunz
    • ,
  • Phyllis Spuls, University of Amsterdam and VU University Amsterdam
    • ,
  • Laura B. von Kobyletzki, Lund University
    • ,
  • Regina Fölster-Holst, Kiel University
    • ,
  • Pavel V. Chernyshov, Bogomolets National Medical University
    • ,
  • Stéphanie Cristen-Zaech, University of Lausanne
    • ,
  • Annice Heratizadeh, Hannover Medical School
    • ,
  • Johannes Ring, Technische Universität München, Christiane-Kühne Center for Allergy Research and Education (CK-Care)
    • ,
  • Christian Vestergaard

Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.

OriginalsprogEngelsk
TidsskriftJournal of the European Academy of Dermatology and Venereology : JEADV
Vol/bind34
Nummer6
Sider (fra-til)e241-e242
ISSN0926-9959
DOI
StatusUdgivet - jun. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 185783692